Evaxion biotech announces q4 and full-year 2020 financial results and provides business update

Copenhagen, denmark, april 06, 2021 (globe newswire) -- evaxion biotech a/s (nasdaq: evax), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the fourth quarter and full year 2020 financial results and provided an operational update.
EVAX Ratings Summary
EVAX Quant Ranking